|
Match
|
Document |
Document Title |
|
|
US20110293723 |
SYNTHETIC NANOCARRIER COMBINATION VACCINES
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are... |
|
|
US20120244182 |
USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance... |
|
|
US20070122428 |
Mutant forms of cholera holotoxin as an adjuvant
Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful... |
|
|
US20150182456 |
HYDROGEL VACCINE FORMULATIONS
This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material... |
|
|
US20070237826 |
Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
The present invention encompasses lipid nano/micro particles, which have been modified, preferably on their surface, to contain a molecule or ligand, which targets the nano/micro particles to a... |
|
|
US20100330101 |
BIFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
A bifunctional composition comprising an intracellularly effective immunomodulating nucleic acid component containing at least one immunostimulatory, immunoinhibitory or immunomodulating motif and... |
|
|
US20060251675 |
Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
The invention relates to a mutant cholera holotoxin having reduced toxicity, which functions both as an adjuvant and an antigen carrier. In a particular embodiment, the cholera holotoxin is... |
|
|
US20120003277 |
NANOEMULSION VACCINES
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more... |
|
|
US20070031458 |
Recombinant Vibrio cholerae strain and vaccine comprising said strain
The present invention relates to a recombinant Vibrio cholerae strain, a vaccine comprising said strain, the use of said strain, and methods for its production. The recombinant strain according to... |
|
|
US20160030721 |
DEVICE, SYSTEM, AND METHOD FOR DELIVERY OF SUGAR GLASS STABILIZED COMPOSITIONS
Devices, methods, and compositions are described that includes an implantable device including one or more compartments. One or more pharmaceutically effective compounds stabilized in a sugar... |
|
|
US20060228375 |
Induction of mucosal immunity by vaccination via the skin route
Methods for generating an immune response at a mucosal surface are described. Compositions suitable for use in the methods for generating an immune response at a mucosal surface are also... |
|
|
US20150202274 |
PURIFICATION OF BACTERIAL VESICLES
A two stage filtration process is used to purify immunogenic bacterial vesicles. A first step separates the vesicles from intact bacteria based on their different sizes, with the smaller vesicles... |
|
|
US20150165016 |
POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE
The invention relates, in part, to the use of compositions of poly N-acetylated glucosamine (PNAG) and antibodies specific to PNAG in the prevention and treatment of infections by certain... |
|
|
US20110182847 |
USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a... |
|
|
US20140328876 |
SYNTHETIC DERIVATIVES OF MPL AND USES THEREOF
In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally... |
|
|
US20060099229 |
Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
Metabolic auxotroph of Vibrio cholerae 0139 synonym Bengal which has a mutation in its hem A gene and which is not capable of synthesizing aminolevulinic acid (ALA) de novo and which is obtained... |
|
|
US20100266640 |
Plant-Derived Cholera and Malaria Vaccine
Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions... |
|
|
US20140242113 |
LIQUID VACCINE PREPARATIONS
This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid... |
|
|
US20090010964 |
Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines
The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response... |
|
|
US20060246094 |
Inactivated vibrio cholerae vaccine in tablet form
The present invention has applications in the field of vaccinology, specifically as an orally administered vaccine for the cholera infection. The aim is to develop a vaccine for oral... |
|
|
US20100266632 |
VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR
An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1),... |
|
|
US20090214531 |
Methods and Compositions for Treating and Preventing Bacterial Infections
The invention features methods and compositions for treating or preventing Gram-negative bacterial infections. |
|
|
US20060171966 |
Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype
The invention relates to novel types of Vibrio cholerae that are useful for vaccines and immunological compositions. |
|
|
US20060233837 |
Vibrio cholerae vaccine candidates, the methods of their constructing and medicinal preparations derived thereof
A single oral administration dose medicinal preparation is derived from Vibrio cholerae vaccine strains which have a disrupted hemagglutinin protease gene and which are tagged with celA coding... |
|
|
US20070059286 |
Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
The present invention describes DNA vaccines that encode for and direct the coincident expression of an antigen and an ADP-ribosyltransferase toxin that is devoid of ADPribosyltransferase activity... |